Persistence of visual improvement one month after discontinuation of treatment · participants with chronic CME (≥ 4 months) following cataract surgery
It is very uncertain whether NSAID changes persistence of visual improvement one month after discontinuation of… compared with placebo (very low certainty).
1 finding from 1 review
Improvement in leakage on FFA Â · participants with chronic CME (≥ 4 months) following cataract surgery
It is very uncertain whether NSAID changes improvement in leakage on FFA Â compared with placebo (very low certainty).
1 finding from 1 review
Global improvement · Individuals with autism spectrum disorder
Music therapy probably leads to higher global improvement compared with placebo therapy or standard care (moderate certainty).
1 finding from 1 review
Social interaction · Individuals with autism spectrum disorder
1 finding from 1 review
Non‐verbal communication · Individuals with autism spectrum disorder
1 finding from 1 review
Verbal communication · Individuals with autism spectrum disorder
1 finding from 1 review
Quality of life · Individuals with autism spectrum disorder
1 finding from 1 review
Autism symptom severity Measured by: parent‐reported autism symptoms on standardised autism screening and diagnostic instruments (lower scores indicate less severe autism symptoms) · Individuals with autism spectrum disorder
1 finding from 1 review
Adverse events Any serious or non‐serious adverse event · Individuals with autism spectrum disorder
Music therapy showed no clear difference in adverse events Any serious or non‐serious adverse event compared with placebo therapy or standard care (moderate certainty).
1 finding from 1 review
Induction of labour · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with an improvement in disability scale used in the original study · people with multifocal motor neuropathy
IVIg showed no clear difference in proportion of participants with an improvement in disability scale… compared with placebo (low certainty).
1 finding from 1 review
RR 3 [0.89, 10.12]
18 participants
Low
Proportion of participants with an improvement of muscle strength · people with multifocal motor neuropathy
IVIg may leads to higher proportion of participants with an improvement of muscle strength compared with placebo (low certainty).
1 finding from 1 review
RR 11 [2.86, 42.25]
27 participants
Low
Proportion of participants with an improvement in disability at 12 months or later · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants in which at least 1 conduction block resolved after therapy · people with multifocal motor neuropathy
IVIg showed no clear difference in proportion of participants in which at least 1 conduction block… compared with placebo (low certainty).
1 finding from 1 review
RR 7 [0.95, 51.7]
28 participants
Low
Maintenance · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal · people with multifocal motor neuropathy
IVIg probably leads to higher proportion of IVIg‐treated participants with an increase in… compared with placebo (moderate certainty).
1 finding from 1 review
RR 2.43 [1.13, 5.24]
42 participants
Moderate
Proportion of IVIg‐treated participants with a decrease in muscle strength during controlled IVIg withdrawal · people with multifocal motor neuropathy
IVIg probably leads to lower proportion of IVIg‐treated participants with a decrease in muscle… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.2 [0.07, 0.54]
42 participants
Moderate
Proportion of participants with side effects attributable to treatment · people with multifocal motor neuropathy
It is very uncertain whether IVIg changes proportion of participants with side effects attributable to treatment compared with placebo (very low certainty).
1 finding from 1 review
RR 10.33 [2.15, 49.77]
21 participants
Very low
Clinical vertebral fractures · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Wrist fractures · pPostmenopausal women at higher risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes wrist fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.64 [0.33, 1.24]
Studies not reported
Very low